Tag: vector

Planful Wins 2025 AI Breakthrough Award for Innovation in AI-Based Analytics

Company Recognized for Exceptional Innovation in Applying AI To Complex Financial Data and Processes SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- Planful Inc., the pioneer...

New Go Direct Sensors from Vernier Science Education Help High School- and College-Level Students Explore Real-World Phenomena

The Go Direct 2-Axis Force Plate and Go Direct Turbidity Sensor help STEM and CTE students easily collect and analyze data during a wide...

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

Zilliz Announces General Availability of Zilliz Cloud BYOC on GCP

Expands Enterprise Vector Search Options with New Security, Compliance, and Automation Features REDWOOD CITY, Calif., June 24, 2025 /PRNewswire/ -- Zilliz, the company behind the open-source...

GEM OIL COMPLETES PHASE ONE DRILLING AT K2 ANOMALY, ATHABASCA BASIN

REGINA, SK, June 23, 2025 /CNW/ - GEM Oil Inc. ("GEM" or the "Company") is pleased to announce the successful completion of its Phase...

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

2024 Cell and Gene Therapy Market Set for Breakthrough Growth, Says BCC Research

"Comprehensive Review Highlights Market Growth, Innovation, and Investment Trends Driving the Future of Cell and Gene Therapy Tools, Biomanufacturing, and Gene Synthesis" BOSTON, June 20, 2025...

The worlds First Fixed Fee Blockchain Appoints Former CFO of CitiGroup Finance

LONDON, June 20, 2025 /PRNewswire/ -- Vector Smart Chain (VSC), a Layer 1 blockchain protocol, has announced two strategic developments: the implementation of a...

Microbial Food Ingredient Market to Hit USD 4.29 Billion by 2031, Driven by Clean Label and Probiotic Demand ‘ | Valuates Reports’

Microbial Food Ingredient Market is Segmented by Type (Starter Cultures, Protective Cultures, Probiotic Cultures), by Application (Food, Drinks, Others). BANGALORE, India, June 16, 2025 /PRNewswire/...

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate...

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

Zilliz Transforms Video Surveillance Industry with AI-Powered Vector Database Solutions

Leading surveillance providers leverage Zilliz Cloud to overcome data overload challenges, enabling real-time threat detection and sub-second video search across enterprise installations. REDWOOD SHORES, Calif.,...

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsVector

ICE Box Claims Evaluated: Personal Document Storage System for Organization & Secure Protection in Case of Emergencies

GDDY Investor News: If You Have Suffered Losses in GoDaddy Inc. (NYSE: GDDY), You Are Encouraged to Contact The Rosen Law Firm About Your...

XM Announces Enhanced Trading Conditions and Opportunities for Global Traders – Featuring Partner Code 274PQ